The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Is there a future for PI3Kis in CLL?
Matthew Davids, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, discusses the role of PI3K inhibitors (PI3Kis) in treating relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). He notes that these drugs are associated with immune-mediated toxicities and a higher rate of infections, which limits their use to later lines of therapy. Dr Davids expresses hope that further research may lead to ways to mitigate these toxicities, allowing for renewed use of this drug class in CLL treatment. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting work with all of the relevant companies working in this space.
